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Abstract 
Introduction: It is well established that thyroid hormones significantly affect skeletal muscle function, causing symptoms like myalgia 
and muscle weakness. Hypothyroid patients present increased levels of creatine kinase (CK), indicating muscle destruction. Lately, we 
proposed new serum markers of muscle disturbances in thyroid disorders: titin (TTN) and dystrophin (DMD). The aim of this study is to 
determine the association between thyroid status, muscle metabolism, and serum levels of TTN and DMD in patients affected by hypo- 
and hyperthyroidism, before and after the treatment.
Material and methods: In the study 56 subjects were enrolled. The studied group consisted of 16 patients with newly diagnosed overt 
hypothyroidism and 20 patients with hyperthyroidism. Twenty healthy controls were also included in the study. Body composition, 
thyroid hormones, and biochemical markers of muscle deterioration levels were evaluated before and after restoration of euthyroidism.
Results: Dystrophin and TTN levels were noticeably lower in the hypothyroid group and hyperthyroid group in comparison with controls, 
at the border of statistical significance. Along with the thyroid hormones and CK normalisation, DMD levels increased in the hypothyroid 
group, with no significant lowering of TTN levels. However, TTN concentrations and the fT3/fT4 ratio became significantly lower than in 
controls. Hyperthyroid patients experienced no significant changes in TTN and DMD. 
Conclusions: The presented data indicate that TTN and DMD are potential new markers of musculoskeletal deterioration in thyroid 
disorders. In addition, the shift in TTN and DMD serum concentrations after the treatment of hypothyroidism accompanied by decreased 
fT3/fT4 ratio suggest the influence of the chosen therapeutic approach on muscle metabolism. (Endokrynol Pol 2021; 72 (1): 1–7)
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Introduction
Patients affected by thyroid disorders, including those 
suffering from hypothyroidism and those with hy-
perthyroidism, often report accompanying muscular 
symptoms such as weakness, fatigability, muscle pain, 
stiffness, or cramps. However, the prevalence of these 
signs and symptoms is variable [1–4].
The majority of these symptoms, except in muscle 
strength, can be evaluated only subjectively by the pa-
tient. Kocabas et al. [5] showed that the muscle strength 
of patients with hypo- or hyperthyroidism is signifi-
cantly reduced in comparison to the control group. In-
terestingly, after restoring euthyroidism, the strength 
parameters improved only in the hyperthyroid group; 
this may be related to the fact that hypothyroidism usu-
ally lasts much longer than hyperthyroidism until the 
moment of treatment, which may lead to irreversible 
changes at the cellular level of the muscles.
Due to the high complexity of the muscle cells’ 
physiology and the importance of thyroid hormones 
in their homeostasis [6, 7], the direct cause of the 
symptoms mentioned above cannot be clearly iden-
tified yet. In the case of overt hypothyroidism, the 
negative influence of thyroid disorder on muscle 
tissue can be visualised by the elevation of creatine 
kinase (CK) activity, as well as lactate dehydrogenase 
(LDH) in serum [8]. The CK serum activity, because 
it is a component of the muscle fibre cytosol, is gen-
erally positively correlated with progressing muscle 
damage [9] Although similar changes do not appear 
in hyperthyroid patients, these subjects usually expe-
rience a statistically significant decrease in CK levels 
due to increased renal filtration, visualised by elevated 
estimated glomerular filtration rate (eGFR) [10]. Other 
useful markers of muscle dysfunction in the case of 
thyroid function disturbances have not been widely 
described to date. 
In the recent study conducted by our team in 2018 
[11], the new markers of disturbances in muscle tissue 
metabolism due to changes in the thyrometabolic states 
were proposed. Decreased titin (TTN) and dystrophin 
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The measurements of TSH, fT3, fT4, CK, and glucose concentrations 
were done with the use of a Hitachi Cobas e601 chemiluminescent 
analyser (Roche Diagnostics). Thyroid autoantibody concentrations 
were assessed by a radioimmunological method with the use of 
commercially available BRAMHS anti-TPO, anti-Tg, and TRAK RIA 
kits, and a scintillation gamma counter (LKB Wallac Clini Gamma 
1272). Irisin serum concentration was measured using ELISA As-
say Kit from Phoenix Pharmaceuticals — Catalogue No. EK-067-29 
— Irisin, Recombinant (Human, Rat, Mouse, Canine) ELISA Kit. 
DMD and TTN concentrations were evaluated with ELISA Assay 
Kit by Shanghai Sunred Biological Technology. Both kits (Catalogue 
No. 201-12-5116 for TTN and 201-12-1446 for DMD) are based on 
the principle of double-antibody sandwich technique, with the 
use of monoclonal antibodies. These assays have high sensitivity 
and specificity for the detection of TTN and DMD, and no signifi-
cant cross-reactivity of interference between TTN/DMD and their 
analogues was observed. The AIXPLORER system by Supersonic 
Imagine was used for ultrasonographic examination of the thy-
roid gland, and the Tanita MC 180 MA analyser was used for the 
evaluation of body composition. The used normal ranges included: 
TSH — 0.27–4.2 μIU/ml, fT3 — 3.90–6.70 pmol/L, fT4 — 11.5–21.0 
pmol/L, CK — 26.0–140.0 U/L, glucose — 70.0–99.0 mg/dL, TRAb 
< 2.0 IU/L, TPOAb < 34 IU/mL, TgAb 10–115 IU/mL.
The diagnosis
When the TSH concentration exceeded the reference range and 
free thyroid hormones were below the normal values, the diagnosis 
of overt hypothyroidism was established. Enrolled patients were 
diagnosed with overt hyperthyroidism on the other hand, when 
a decrease in TSH concentration below the normal value occurred, 
along with an increase in free thyroid hormones concentrations 
above the reference range. To establish the diagnosis of autoimmune 
thyroid disease, the detection of at least one elevated anti-thyroid 
autoantibody titre and presence of sonographic signs of chronic 
thyroid inflammation were required. Overt hyperthyroidism ac-
companied by the elevation of TRAb titres and typical thyroid ultra-
sound features was mandatory for the diagnosis of Graves’ disease.
Statistical analysis
STATISTICA software by StatSoft was applied to analyse the ac-
quired data. Normality was checked by the Shapiro-Wilk test, and 
the equality of variances was analysed with the use of Levene’s test. 
Taking into consideration the small size of the analysed groups, 
statistically significant differences in normality, and equality of 
variances between groups, non-parametric tests were used. To 
compare analysed parameters between two groups, a two-tailed 
Mann-Whitney U test was applied, while for more than two groups, 
Kruskal-Wallis one-way analysis of variance was used with the 
following post-hoc analysis. To analyse the difference between 
the two related samples, the Wilcoxon signed-rank test was used. 
A p-value of less than 0.05 was considered statistically significant.
Results
Bodyweight, age, BMI, FM, FFM, Fat%, MM, and 
visceral fat rating have not differed significantly be-
tween the study groups at baseline and controls, as 
well as gender distribution; however, the difference in 
bodyweight and FM between groups almost reached 
statistical significance (Tab. 1). Nevertheless, BMI and 
Fat% seem to be more objective parameters, because 
they take into account the differences in the height of 
patients. The analysed groups presented significantly 
different levels of TSH, fT4, fT3, CK, aTPO, aTg, and 
TRAb. The glucose levels were increased in the hyper-
(DMD) serum concentrations were shown on a large 
group of patients affected by overt hypo- or hyperthy-
roidism, compared with healthy controls. The authors 
hypothesised that changes in serum concentrations 
of these large, structural muscle tissue proteins might 
reflect the alterations in muscle tissue metabolism. It 
was concluded, because the dynamics of those changes 
were in contrast to the case of CK, that the dysfunction 
of muscle fibres might be the result of decreased pro-
duction of these proteins, not leakage from destructed 
cells. It is worth noting that it was the first description 
of the dynamics of changes of TTN and DMD and their 
potential usefulness in the assessment of thyroid disor-
ders. However, the serum concentrations of TTN and 
DMD have not yet been evaluated after the restoration 
of euthyroidism.
The aim of this study is to determine the associa-
tion between thyroid status and serum levels of TTN 
and DMD in patients affected by overt hypo- and 
hyperthyroidism, before and after the restoration 
of euthyroidism, which could provide more data 




The study was conducted among the population of the Wielko-
polskie Voivodeship in Poland. All participants are Caucasians 
of Polish origin. A total of 56 subjects were enrolled in the study. 
The studied group consisted of 16 patients with newly diagnosed 
severe overt hypothyroidism due to autoimmune thyroid disease 
and 20 treatment-naive patients with severe overt hyperthyroidism 
affected by Graves’ disease. Additionally, 20 healthy control subjects 
were included in the study. The exclusion criteria were similar to 
those applied in the previous researches [11]. The Bioethical Com-
mittee at Poznan University of Medical Sciences approved the study 
(Resolution no. 923/13).  
Study protocol
All engaged subjects underwent a full clinical examination, 
thyroid ultrasound, and assessment of body composition. 
The laboratory measurements included irisin concentrations, 
thyroid-related hormones concentrations (thyroid-stimulating 
hormone [TSH], free triiodothyronine [fT3], free thyroxine 
[fT4]), titres of anti-thyroid autoantibodies (serum anti-thyroid 
peroxidase antibodies [TPOAb], anti-thyroglobulin antibodies 
[TgAb], anti-TSH receptor autoantibodies [TRAb/TRAK]), and 
muscle protein concentrations as biochemical markers of muscle 
dysfunction and/or injury (CK, DMD, TTN). Additionally, se-
rum fasting glucose concentrations were measured, and the 
fT3/fT4 ratio was calculated. The body composition assessment 
was performed using bioelectrical impedance analysis (BIA), as-
sessing body weight, body mass index (BMI), fat mass (FM), per-
cent of fat mass (Fat%), free-fat mass (FFM), muscle mass (MM), 
and visceral fat rating. Venous blood samples were gathered and 
BIA analysed in a consistent manner after 8 hours of fasting. All 
measurements were repeated after restoring euthyroidism due 
to applied treatment — L-thyroxine substitution in hypothyroid 
patients, treatment with anti-thyroid drugs, radioiodine therapy, 
or thyroidectomy in the case of hyperthyroidism.
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Table 1. The characteristics and statistical differences of the measured values at baseline in three study groups: patients 























































































































































































TSH — thyroid-stimulating hormone; fT3 — free triiodothyronine; fT4 — free thyroxine; TPOAb — anti-thyroid peroxidase antibodies; TgAb — anti-thyroglobulin 
antibodies; TRAb — anti-TSH receptor autoantibodies; CK — creatine kinase; DMD — dystrophin; TTN — titin; BMI — body mass index; FM — fat mass,  
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thyroid group compared with hypothyroid patients and 
controls. Hypothyroid patients presented decreased 
concentrations of irisin in comparison with the other 
two groups which did not differ statistically in this re-
spect. The difference in DMD and TTN concentrations 
between groups did not reach statistical significance; 
however, DMD and TTN levels were noticeably lower 
in the hypothyroid group and hyperthyroid group in 
comparison with controls. Before treatment in the hypo-
thyroid and hyperthyroid groups the fT3/fT4 ratio was 
higher than in controls; however, in the second group 
at the border of statistical significance. The detailed 
results are presented in Table 1.
The mean observation time for reaching hormonal 
normalisation was 313.40 days or approximately 
10.28 months for the hypothyroid group and 225.67 
days or approximately 7.40 months for the hyperthyroid 
group. The hypothyroid group after the restoration 
of euthyroidism experienced slight weight loss, and 
a decrease in MM and FFM at the border of statistical 
significance (Tab. 2). There was no difference in FM and 
Fat%. Along with the TSH, fT3, and fT4 normalisation, 
these patients showed normalisation of CK levels and 
significant increase in irisin and DMD levels. Median 
TTN concentrations were lower after achieving euthy-
roidism, but the difference was not statistically signifi-
cant. In the hyperthyroid group after normalisation of 
thyroid hormones, we can observe an increase in body 
weight, BMI, FM, Fat%, and CK levels and a decrease in 
glucose concentrations. There was no statistically sig-
nificant change in MM, TTN, DMD, and irisin levels. In 
both groups, the fT3/fT4 ratio decreased after treatment. 
After the treatment, patients in study groups did 
not differ statistically in body composition, as well as 
TSH, fT3, fT4, CK, DMD, and glucose, compared with 
controls. The TTN levels were significantly lower in the 
hypothyroid group after achieving euthyroidism than 
in controls. The fT3/fT4 ratio was significantly lower in 
the hypothyroid group compared with the hyperthy-
roid group and controls, with no significant difference 
between hyperthyroid patients and controls. The de-
tailed results are presented in Table 2. Due to the low 
statistical power of the group, the presented results are 
preliminary and need further investigation.
Discussion
The study published by our team in 2018 provides only 
available data about the changes in the concentration of 
TTN and DMD in patients with thyroid disorders [11].
The current research emphasises in particular the is-
sue of the usefulness of TTN and DMD as new markers 
of muscle damage during thyroid disorders. Some of 
the measurements were conducted once more to evalu-
ate their accuracy on a different group of patients.  In 
general, the results of the present study are consistent 
with those of the previous one. However, in the hypo-
thyroid group the decrease in MM after the restoration 
of euthyroidism did not reach statistical significance, 
probably due to the smaller sample size. Similarly, TTN 
and DMD levels at baseline differed between groups at 
the border of statistical significance. Nevertheless, the 
trend in TTN and DMD levels at baseline is comparable 
to the previous research — both concentrations are 
lower in hypo- and hyperthyroid patients.
After the restoration of euthyroidism, only in hypo-
thyroid patients, we can observe a statistically signifi-
cant increase in levels of DMD, and even some slight 
lowering of TTN when compared to levels at baseline. 
However, after treatment, TTN concentrations became 
significantly lower than in controls. In hyperthyroid 
groups, there is no statistically significant difference 
in TTN and DMD levels before and after treatment, 
but they remain noticeably lower than in the control 
group. The lack of definite normalisation of TTN and 
DMD after achieving euthyroidism might reflect some 
profound changes in muscle metabolism, occurring 
even after treatment.
The biochemistry and physiology of muscle cells are 
very complex, and thyroid hormones play a significant 
role in their homeostasis, including metabolic rate, 
energy expenditure, and glucose uptake.
Genes critical for muscle function and metabolism 
are regulated by triiodothyronine, which is derived 
from tetraiodothyronine due to DIO2 activity [12]. One 
of the crucial roles of T3 action on muscle fibres, depen-
dent on thyroid status [13], is its possibility to change 
fibre type from slow-twitch (type 1) to fast-twitch type 
(type IIa, IIx, IIb) by regulation of genes MYH1, 2, 4, 
and 7, which determine myosin heavy chain type [14]. 
We assume that this kind of TH-dependent muscle 
plasticity affects other cytoskeletal proteins such as titin 
and dystrophin.
With switching fibre-type, there is also a change in 
metabolic profile. Slow-twitch fibres are oxidative and 
contain more mitochondria and myoglobin. In turn, 
fast-twitch fibres are glycolytic, with higher concentra-
tions of phosphocreatine [14].
Brennan et al. examined muscle biopsies of hy-
perthyroid patients before and after the correction of 
hyperthyroidism. The first finding is a decreased level 
of myosin heavy chain I (MHC I; slow-twitch fibres) and 
increased levels of MHCIIa and MHCIIx (fast-twitch) 
mRNAs in hyperthyroidism. After the restoration of 
the euthyroid state, consecutively, MHCI increased 
and MHCIIa/IIx decreased. The second finding was 
a decreased overall metabolic rate and reduced protein 
turnover [15].
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On the other hand, Monforte et al. investigated hypo-
thyroid patients. Before treatment, histological findings 
revealed atrophy of type II fibres and abnormalities in 
glycogen deposition and oxidative pattern. Biochemical 
tests showed increased muscle glycogen and reduced 
activity of glycolysis and glycogenolysis enzymes. After 
treatment, laboratory parameters returned to normal, but 
some histological abnormalities persisted. The authors 
hypothesise that these histological pathologies may be 
the effect of irreversible damage in skeletal muscle, which 
is in line with our assumptions [16]. We theorise that 
after treatment of hyper- or hypothyroidism, metabolic 
parameters of muscles are restored to normal; however, 
with long-lasting thyrometabolic defects, some of them 
may become irreversible and manifest itself as the lack 
of normalisation of TTN and DMD.
Table 2. The characteristics and statistical differences of the measured values at baseline and after restoring euthyroidism 
in patients affected by hyperthyroidism and in patients affected by hypothyroidism. Statistically significant differences 
(p < 0.05) are marked [*]
Median
[25–75%]































































































































































































TSH — thyroid-stimulating hormone; fT3 — free triiodothyronine; fT4 — free thyroxine; TPOAb — anti-thyroid peroxidase antibodies; TgAb — anti-thyroglobulin 
antibodies; TRAb — anti-TSH receptor autoantibodies; CK — creatine kinase; DMD — dystrophin; TTN — titin; BMI — body mass index; FM — fat mass;  
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Additionally, we analysed the fT3/fT4 ratio. It was 
higher at the baseline in both hyper- and hypothy-
roid groups than in controls — comparable with the 
previous study of Mortoglou and Candiloros [17]. In 
hyperthyroid patients, the ratio is higher mainly due to 
excessive production of T3, and in hypothyroid subjects 
because of a decline in T4 concentration. After restora-
tion of euthyroidism, the fT3/fT4 ratio in both groups 
decreased significantly, with median ratio values in 
hypothyroid patients lower than in the control group. 
A similar lowering of the fT3/fT4 ratio in hypothyroid 
patients after treatment was observed after analys-
ing results by Hernik et al. [18]. It is probably due to 
the use of preparations containing only L-thyroxin in 
the management of hypothyroidism. There are still 
conflicting opinions about the combined L-thyroxin 
and L-triiodothyronine treatment; however, recom-
mendations for such a therapeutic approach have 
recently been incorporated into the guidelines of the 
British Thyroid Association [19]. The use of combined 
preparation might result in the normalisation of the 
fT3/fT4 ratio.
Because, after the treatment of hypothyroid pa-
tients, the fT3/fT4 ratio was significantly lower than 
in controls accompanied by some shift in the levels of 
TTN and DMD and lowering of muscle mass, it might 
be possible that the change in fT3/fT4 ratio alters the 
composition of muscle fibres. Thus, alteration in the syn-
thesis and/or catabolism of large structural muscle fibre 
proteins is reflected by different dynamics of changes in 
TTN and DMD serum concentrations. However, such 
a hypothesis should be confirmed on a larger group 
of patients, preferably both on groups treated with L-
thyroxin monotherapy and on those treated with com-
bined L-thyroxin and L-triiodothyronine treatment.
Unfortunately, our study has several limitations. The 
smaller sample size, compared to the previous survey, 
affects the explicitness of the results obtained, although 
the trends observed remain constant. What is more, 
body composition could be assessed with the use of 
DXA or MRI examination for more accurate measure-
ments than BIA spectroscopy. However, results of 
a recent study by Esco et al. show that BIA devices are 
acceptable alternatives to DXA for BF%, FM, and FFM 
assessment in clinical practice [20]. Hence, the obtained 
data should be considered as preliminary.
Conclusions
Thyroid disorders can lead to great disturbances in 
muscle tissue, presented by changes in serum con-
centrations of small muscle enzymes, like CK or large 
structural proteins, like DMD or TTN; however, the pre-
sented dynamics of changes is different. What is more, 
changes in thyroid function, especially hypothyroidism, 
lead to disturbances resulting in decreased irisin levels 
— myokine produced by the muscle fibres. TTN and 
DMD may be the potential new markers of musculo-
skeletal deterioration in thyroid disorders. In addition, 
the shift in TTN and DMD serum concentrations after 
the treatment of hypothyroidism accompanied by 
a significant decrease in the fT3/fT4 ratio may suggest 
the influence of the chosen therapeutic approach on 
muscle metabolism. However, all of these promising 
and interesting issues should be evaluated further in 
more detailed studies on a large cohort of subjects.
Acknowledgments
This research was funded from the Statutory Funds of 
the Department of Endocrinology.
Conflict of interest
The authors do not have any conflict of interest related 
to this manuscript.
References
1. Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular find-
ings in thyroid dysfunction: a prospective clinical and electrodiag-
nostic study. J Neurol Neurosurg Psychiatry. 2000; 68(6): 750–755, 
doi: 10.1136/jnnp.68.6.750, indexed in Pubmed: 10811699.
2. Olson BR, Klein I, Benner R, et al. Hyperthyroid myopathy 
and the response to treatment. Thyroid. 1991; 1(2): 137–141, 
doi: 10.1089/thy.1991.1.137, indexed in Pubmed: 1688015.
3. Da Nóbrega AC, Vaisman M, De Araújo CG. Skeletal muscle function 
and body composition of patients with hyperthyroidism. Med Sci 
Sports Exerc. 1997; 29(2): 175–180, doi: 10.1097/00005768-199702000-000
02, indexed in Pubmed: 9044219.
4. Khaleeli AA, Edwards RH. Effect of treatment on skeletal muscle 
dysfunction in hypothyroidism. Clin Sci (Lond). 1984; 66(1): 63–68, 
doi: 10.1042/cs0660063, indexed in Pubmed: 6606523.
5. Kocabas H, Yazicioglu G, Karaman N, et al. Isokinetic evaluation of 
muscle strength in patients with thyroid dysfunction. Isokinetics Exerci 
Sci. 2009; 17(2): 69–72, doi: 10.3233/ies-2009-0335.
6. Gruener R, Stern LZ, Payne C, et al. Hyperthyroid myopathy. Intracel-
lular electrophysiological measurements in biopsied human intercostal 
muscle. J Neurol Sci. 1975; 24(3): 339–349, doi: 10.1016/0022-510x(75)902
54-3, indexed in Pubmed: 1117309.
7. Brennan MD, Powell C, Kaufman KR, et al. The impact of overt and 
subclinical hyperthyroidism on skeletal muscle. Thyroid. 2006; 16(4): 
375–380, doi: 10.1089/thy.2006.16.375, indexed in Pubmed: 16646684.
8. McGrowder DA, Fraser YP, Gordon L, et al. Serum creatine kinase and 
lactate dehydrogenase activities in patients with thyroid disorders. Niger 
J Clin Pract. 2011; 14(4): 454–459, doi: 10.4103/1119-3077.91755, indexed 
in Pubmed: 22248949.
9. Klein SM, Prantl L, Geis S, et al. Circulating serum CK level vs. muscle 
impairment for in situ monitoring burden of  disease  in  Mdx-mice. 
Clin Hemorheol Microcirc. 2017; 65(4): 327–334, doi: 10.3233/CH-16195, 
indexed in Pubmed: 27716655.
10. Sönmez E, Bulur O, Ertugrul DT, et al. Hyperthyroidism influences renal 
function. Endocrine. 2019; 65(1): 144–148, doi: 10.1007/s12020-019-01903-2, 
indexed in Pubmed: 30904999.
11. Zybek-Kocik A, Sawicka-Gutaj N, Szczepanek-Parulska E, et al. The asso-
ciation between irisin and muscle metabolism in different thyroid disor-
ders. Clin Endocrinol (Oxf). 2018; 88(3): 460–467, doi: 10.1111/cen.13527, 
indexed in Pubmed: 29197093.
12. Lee JW, Kim NH, Milanesi A. Thyroid Hormone Signaling in Muscle 
Development, Repair and Metabolism. J Endocrinol Diabetes Obes. 2014; 
2(3): 1046–15, indexed in Pubmed: 25866834.
13. Simonides WS, van Hardeveld C. Thyroid hormone as a determinant of 
metabolic and contractile phenotype of skeletal muscle. Thyroid. 2008; 
18(2): 205–216, doi: 10.1089/thy.2007.0256, indexed in Pubmed: 18279021.
14. Bloise FF, Cordeiro A, Ortiga-Carvalho TM. Role of thyroid hormone 
in skeletal muscle physiology. J Endocrinol. 2018; 236(1): R57–R68, 
doi: 10.1530/JOE-16-0611, indexed in Pubmed: 29051191.
7










15. Brennan MD, Coenen-Schimke JM, Bigelow ML, et al. Changes in skeletal 
muscle protein metabolism and myosin heavy chain isoform messenger 
ribonucleic acid abundance after treatment of hyperthyroidism. J Clin 
Endocrinol Metab. 2006; 91(11): 4650–4656, doi:  10.1210/jc.2006-1074, 
indexed in Pubmed: 16940450.
16. Monforte R, Fernández-Solà J, Casademont J, et al. [Hypothyroid my-
opathy. A clinical and histologic prospective study of 19 patients]. Med 
Clin (Barc). 1990; 95: 126–129, indexed in Pubmed: 2250530.
17. Mortoglou A, Candiloros H. The serum triiodothyronine to thy-
roxine (T3/T4) ratio in various thyroid disorders and after Levo-
thyroxine replacement therapy. Hormones (Athens). 2004; 3(2): 
120–126, doi:  10.14310/horm.2002.11120, indexed in Pubmed:
16982586.
18. Hernik A, Szczepanek-Parulska E, Filipowicz D, et al. The hepcidin 
concentration decreases in hypothyroid patients with Hashimoto’s 
thyroiditis following restoration of euthyroidism. Sci Rep. 2019; 9(1): 
16222, doi: 10.1038/s41598-019-52715-3, indexed in Pubmed: 31700042.
19. Okosieme O, Gilbert J, Abraham P, et al. Management of primary 
hypothyroidism: statement by the British Thyroid Association 
Executive Committee. Clin Endocrinol (Oxf). 2016; 84(6): 799–808, 
doi: 10.1111/cen.12824, indexed in Pubmed: 26010808.
20. Esco MR, Fedewa MV, Freeborn TJ, et al. Agreement between supine 
and standing bioimpedance spectroscopy devices and dual-energy X-
ray absorptiometry for body composition determination. Clin Physiol 
Funct Imaging. 2019; 39(5): 355–361, doi: 10.1111/cpf.12585, indexed in 
Pubmed: 31287228.
